bit.bio | featured in technology networks
CAMBRIDGE, Wednesday 5 January 2022 —Technology Networks interviews Dr. Mark Kotter, CEO of bit.bio.
The interview digs deep into how bit.bio’s next generation cellular reprogramming technology, opti-ox™, is enabling scientists in research and drug discovery to overcome the shared challenges presented by human muscle models.
Mark explains how pioneering work conducted in the 1980’s sparked the development of opti-ox, and when this uniquely engineered genetic switch is applied to cell reprogramming it enables the deterministic induction of a new cell identity from human iPSCs, into any cell type on a vast scale. opti-ox forms the basis of bit.bio’s ioCells and within this interview he goes into detail about the benefits and key applications of ioSkeletal Myocytes.
He talks about one of the big challenges facing biomedical research, the lack of a consistent and scalable supply of human cells and why our ioSkeletal Myocytes offer a solution. Really hitting home the benefits, Mark says “The front-end validation and definition of ioSkeletal Myocytes is only required once. This removes the need for continuous validation of new batches as it is commonly required for primary cells. This translates into a significant saving in time, effort and cost over the course of extended research projects compared to using conventional muscle cell models.”
Read the article to find out more about the development of bit.bio’s next-generation gene engineering technology, opti-ox and learn how it drives consistency and reliability in our ioSkeletal Myocytes.